We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Other degenerative diseases of the nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Frontotemporal dementia (FTD) is a common cause of young onset dementia. Its effect on people of working age with young families represents a major health and economic burden on society. The only known risk factors for FTD at present are genetic with abnormalities (mutations) in three genes accounting for the majority of familial FTD, called progranulin, tau and chromosome 9 open reading frame 72. There are now promising avenues for treatment of these disorders but we still do not know when drugs should be started or how we should measure the response to treatment. This study investigates people who have genetic (inherited) FTD, including both people who have developed symptoms and also people who have a risk of developing symptoms in the future because they carry the abnormal genetic mutation. This allows a window into the earliest changes in the disease process. Study participants will have psychology testing (tests of memory, language, behaviour etc.), brain imaging, blood tests and spinal fluid collection (by lumbar puncture) in order to investigate the patterns of change in these different tests at different stages of the disorder. By studying individuals who carry the disease mutation and are thus destined to develop the disease we can understand the development from the very earliest changes, which would be the best time to start any treatment whilst the person remains well. The key objectives are to develop of markers which help identify the disease at its earliest stage as well as markers that allow the progression of the disease to be tracked. The eventual aim will be to use these markers in future clinical trials of drugs in genetic FTD. The results of this project will also lead to improvement in the recognition and diagnosis of genetic FTD as well as provide improved information about prognosis for patients and members of their family.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Other;
You can take part if:
You may not be able to take part if:
General exclusion criteria 1. Participant has another medical or psychiatric illness that would interfere in completing assessments or impair the safety of the subject. 2. Participant is pregnant. 3. Contraindications to taking part in an MRI study e.g. pacemaker. Lumbar puncture exclusion criteria 1. Anticoagulants such as warfarin 2. Known coagulation abnormalities – known coagulopathy or platelet count additional ionisation radiation exposure exceeding 10mSv within the last 3 years. There are no exclusionary medications for the GENFI study.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Jonathan
Rohrer
j.rohrer@ucl.ac.uk
The study is sponsored by University College London and funded by Medical Research Council (MRC); NATIONAL INSTITUTE FOR HEALTH AND CARE RESEARCH; .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 18697
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
